Literature DB >> 7508238

Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.

P T Kaumaya1, S Kobs-Conrad, Y H Seo, H Lee, A M VanBuskirk, N Feng, J F Sheridan, V Stevens.   

Abstract

An ideal peptide vaccine should contain both B- and T-cell epitopes. Recognition of antigen by B cells is highly dependent on the three-dimensional conformation of the antigen whereas T cells recognize antigen only after it has been processed to release a peptide fragment which is bound to the major histocompatibility complex (MHC) class II molecule. However, T cells provide 'help' to B cells displaying the same processed, MHC-restricted form of the antigen, demonstrating that the T-cell response to a protein antigen is under genetic control. Thus, strategies for co-inclusion of T cell 'helper' epitopes with the B-cell determinant elicit immune responses that are in most cases genetically restricted to only one or a few alleles of the MHC with limited activity across divergent MHC class II haplotypes. This genetically restricted T cell stimulatory activity of peptides is a serious obstacle and consequently such constructs would be of limited practical value as a vaccine targeted to a majority of an outbred population. In the study described here, we have engineered two peptides to encompass the sequences from the universally immunogenic tetanus toxoid (TT) epitope and the contraceptive vaccine candidate lactate dehydrogenase C4 (LDH-C4). We demonstrate the feasibility of using 'promiscuous' T-cell epitopes colinearly constructed with a defined B-cell epitope to induce high titer antipeptide IgG antibodies specific for native protein antigen LDH-C4 in several inbred strains of mice, outbred mice and rabbits. There appears to be a strong correlation between the capacity for the hybrid peptides to be stimulatory for the corresponding T cells in C57BL/6 (H-2b) and C3H/HeJ (H-2k) mice and their ability to be immunogenic. This correlation, however, appears to break down in H-2d strains of mice since no antibodies were detected in BALB/c and barely detectable levels of antibodies in B10.D2 although activated T cells were detectable. Conversely, high titers of antipeptide antibodies are elicited in some strains (B10.BR (H-2k); C57BL/10 (H-2b) without detectable IL-2 responses. Finally, we show that a determinant which was previously restricted to H-2k can be rendered immunogenic in H-2b with the 'promiscuous' TT epitope. Thus, certain haplotype-restricted immune responses can be bypassed, setting forth the ground work for the design of a universal vaccine by broadening the effective response in a larger number of individuals typical of the genetically diverse outbred human population.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508238     DOI: 10.1002/jmr.300060206

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  22 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine.

Authors:  Chengji Cui; Vernon C Stevens; Steven P Schwendeman
Journal:  Vaccine       Date:  2006-08-17       Impact factor: 3.641

3.  Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

Authors:  David A Montero; Felipe Del Canto; Juan C Salazar; Sandra Céspedes; Leandro Cádiz; Mauricio Arenas-Salinas; José Reyes; Ángel Oñate; Roberto M Vidal
Journal:  NPJ Vaccines       Date:  2020-03-12       Impact factor: 7.344

4.  Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26.

Authors:  Duangkamol Kunthalert; Laura A Novotny; Helen M Massa; Glen C Ulett; Lauren O Bakaletz; Jennelle M Kyd; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

5.  HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Authors:  Megan Jo Miller; Kevin C Foy; Jay P Overholser; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

6.  Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.

Authors:  L O Bakaletz; B J Kennedy; L A Novotny; G Duquesne; J Cohen; Y Lobet
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

Review 7.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

8.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

Authors:  M D Lairmore; A M DiGeorge; S F Conrad; A V Trevino; R B Lal; P T Kaumaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 9.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15

Review 10.  Mimotope vaccination--from allergy to cancer.

Authors:  Regina Knittelfelder; Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.